Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVR Anteris Technologies Global	$3.66 -3.2%	$3.58	$2.34 ▼ $8.79	$131.99M	N/A	202,849 shs	64,006 shs
LNSR LENSAR	$12.19 -3.2%	$12.86	$3.80 ▼ $17.31	$145.55M	0.5	127,598 shs	60,595 shs
PSTV Plus Therapeutics	$0.49 -3.0%	$0.45	$0.16 ▼ $2.31	$48.64M	0.67	19.17 million shs	3.83 million shs
RCEL Avita Medical	$4.53 -0.7%	$5.33	$3.60 ▼ $14.16	$120.59M	1.63	280,900 shs	133,758 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVR Anteris Technologies Global	+2.16%	+3.28%	+16.31%	-20.25%	+377,999,900.00%
LNSR LENSAR	-0.55%	+0.72%	-3.52%	-7.29%	+176.70%
PSTV Plus Therapeutics	+4.14%	-3.42%	-4.64%	+85.05%	-65.16%
RCEL Avita Medical	-1.94%	-6.37%	-20.97%	-26.57%	-51.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVR Anteris Technologies Global	1.8812 of 5 stars	3.5	0.0	2.7	0.0	0.6
LNSR LENSAR	1.0446 of 5 stars	2.0	1.0	3.2	2.5	0.0
PSTV Plus Therapeutics	3.0871 of 5 stars	3.3	5.0	2.4	1.7	0.6
RCEL Avita Medical	1.5465 of 5 stars	3.2	0.0	2.3	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVR Anteris Technologies Global	3.00	Buy	$16.50	350.82% Upside
LNSR LENSAR	2.00	Hold	$15.00	23.05% Upside
PSTV Plus Therapeutics	2.60	Moderate Buy	$8.88	1,711.22% Upside
RCEL Avita Medical	2.40	Hold	$12.40	173.73% Upside

Current Analyst Ratings Breakdown

Latest PSTV, LNSR, RCEL, and AVR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2025	PSTV Plus Therapeutics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
8/11/2025	RCEL Avita Medical	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $8.00
8/8/2025	RCEL Avita Medical	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$19.00 ➝ $18.00
8/8/2025	RCEL Avita Medical	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$3.00
6/27/2025	PSTV Plus Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.50 ➝ $3.00
6/25/2025	PSTV Plus Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold	$9.00
6/6/2025	RCEL Avita Medical	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00
6/5/2025	PSTV Plus Therapeutics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $20.50

(Data available from 8/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVR Anteris Technologies Global	$2.48M	53.24	N/A	N/A	$0.67 per share	5.46
LNSR LENSAR	$53.49M	2.72	N/A	N/A	($1.93) per share	-6.32
PSTV Plus Therapeutics	$5.82M	8.36	N/A	N/A	$0.03 per share	16.33
RCEL Avita Medical	$64.25M	1.88	N/A	N/A	($0.48) per share	-9.44

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVR Anteris Technologies Global	-$76.29M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	11/10/2025 (Estimated)
LNSR LENSAR	-$31.40M	-$4.21	N/A	∞	N/A	-84.49%	-737.30%	-72.60%	11/6/2025 (Estimated)
PSTV Plus Therapeutics	-$12.98M	-$2.24	N/A	N/A	N/A	-357.85%	N/A	-117.72%	11/13/2025 (Estimated)
RCEL Avita Medical	-$61.85M	-$1.97	N/A	N/A	N/A	-68.87%	-632.62%	-71.52%	11/6/2025 (Estimated)

Latest PSTV, LNSR, RCEL, and AVR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	PSTV Plus Therapeutics	-$0.09	-$0.01	+$0.08	-$0.01	$1.08 million	$1.39 million
8/11/2025	Q2 2025 TU	AVR Anteris Technologies Global	-$0.5333	-$0.58	-$0.0467	-$0.58	$0.58 million	$0.62 million
8/7/2025	Q2 2025	LNSR LENSAR	-$0.0750	-$0.15	-$0.0750	-$0.15	$16.55 million	$11.36 million
8/7/2025	Q2 2025	RCEL Avita Medical	-$0.26	-$0.38	-$0.12	-$0.38	$34.27 million	$18.42 million
5/30/2025	Q1 2025	PSTV Plus Therapeutics	-$0.17	-$0.56	-$0.39	-$1.19	$1.11 million	$1.06 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVR Anteris Technologies Global	N/A	N/A	N/A	N/A	N/A
LNSR LENSAR	N/A	N/A	N/A	N/A	N/A
PSTV Plus Therapeutics	N/A	N/A	N/A	N/A	N/A
RCEL Avita Medical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVR Anteris Technologies Global	N/A	2.41	2.38
LNSR LENSAR	N/A	1.52	0.88
PSTV Plus Therapeutics	N/A	1.26	1.26
RCEL Avita Medical	9.39	0.58	0.46

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVR Anteris Technologies Global	N/A
LNSR LENSAR	40.15%
PSTV Plus Therapeutics	3.28%
RCEL Avita Medical	27.66%

Insider Ownership

Company	Insider Ownership
AVR Anteris Technologies Global	4.00%
LNSR LENSAR	66.00%
PSTV Plus Therapeutics	0.79%
RCEL Avita Medical	2.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVR Anteris Technologies Global	138	36.06 million	34.62 million	N/A
LNSR LENSAR	110	11.94 million	4.06 million	Optionable
PSTV Plus Therapeutics	20	99.26 million	98.48 million	Not Optionable
RCEL Avita Medical	130	26.62 million	25.87 million	Optionable

PSTV, LNSR, RCEL, and AVR Headlines

Recent News About These Companies

AVITA ALERT: Bragar Eagel & Squire, P.C. is Investigating AVITA Medical, Inc. on Behalf of Avita Stockholders and Encourages Investors to Contact the Firm

3 hours ago | globenewswire.com

AVITA Medical: Green Shoots Peaking Out From Hard Clay

August 26 at 7:44 PM | seekingalpha.com

Kirby McInerney LLP Announces Investigation Against AVITA Medical, Inc. on Behalf of Investors

August 22, 2025 | globenewswire.com

INVESTOR ALERT: Investigation of AVITA Medical, Inc. (RCEL) Announced by Holzer & Holzer, LLC

August 22, 2025 | globenewswire.com

AVITA Medical, Inc. (RCEL) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

August 21, 2025 | tmcnet.com

AVITA Medical Announces September Investor Conference Participation

August 21, 2025 | globenewswire.com

Securities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

August 21, 2025 | businesswire.com

AVITA Medical, Inc. (RCEL) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

August 21, 2025 | businesswire.com

Robert Mcnamara Acquires 10,000 Shares of Avita Medical (NASDAQ:RCEL) Stock

August 21, 2025 | insidertrades.com

Securities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Announced - Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 20, 2025 | tmcnet.com

Securities Fraud Investigation Into AVITA Medical, Inc. (RCEL) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 20, 2025 | businesswire.com

Avita Medical Announces $15M Equity Placement Agreement

August 19, 2025 | msn.com

Cantor Fitzgerald Expects Reduced Earnings for Avita Medical

August 17, 2025 | marketbeat.com

Cantor Fitzgerald Forecasts Lower Earnings for Avita Medical

August 17, 2025 | americanbankingnews.com

Avita Medical Raises $15M in Private Placement

August 13, 2025 | msn.com

Analysts Are More Bearish On AVITA Medical, Inc. (NASDAQ:RCEL) Than They Used To Be

August 13, 2025 | finance.yahoo.com

Avita Medical completes Australian equity raise

August 13, 2025 | msn.com

AVITA Medical, Inc. (NASDAQ:RCEL) Q2 2025 Earnings Call Transcript

August 13, 2025 | msn.com

Avita Medical’s Earnings Call: Growth Amid Challenges

August 13, 2025 | msn.com

Lake Street Capital Issues Pessimistic Forecast for Avita Medical (NASDAQ:RCEL) Stock Price

August 12, 2025 | marketbeat.com

AVITA Medical Successfully Completes Australian Equity Raise

August 12, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSTV, LNSR, RCEL, and AVR Company Descriptions

Anteris Technologies Global NASDAQ:AVR

$3.66 -0.12 (-3.17%)

As of 04:00 PM Eastern

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.

LENSAR NASDAQ:LNSR

$12.19 -0.40 (-3.18%)

Closing price 04:00 PM Eastern

Extended Trading

$12.20 +0.01 (+0.08%)

As of 04:10 PM Eastern

LENSAR, Inc., a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision. The company also offers ALLY Adaptive Cataract Treatment System, a platform design to femtosecond laser technology features that enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room. LENSAR, Inc. was incorporated in 2004 and is headquartered in Orlando, Florida.

Plus Therapeutics NASDAQ:PSTV

$0.49 -0.02 (-3.01%)

Closing price 04:00 PM Eastern

Extended Trading

$0.50 +0.01 (+1.84%)

As of 06:26 PM Eastern

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.

Avita Medical NASDAQ:RCEL

$4.53 -0.03 (-0.66%)

Closing price 04:00 PM Eastern

Extended Trading

$4.54 +0.01 (+0.33%)

As of 04:10 PM Eastern

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time